These findings underscore the potential of claudin-based strategies in ovarian cancer: for example, CLDN3/4 targeting agents (like CPE fragments or monoclonal antibodies) and perhaps CLDN6/9-directed immunotherapies [CAR T cells against CLDN6 are already in trials for ovarian tumors (1)]. The gene discussed is CLDN6; the disease is ovarian carcinoma.